Investment Analysts’ Weekly Ratings Changes for Prestige Consumer Healthcare (PBH)

Investment Analysts’ Weekly Ratings Changes for Prestige Consumer Healthcare (PBH)

June 6, 2019 Off By administrator

Several analysts have recently updated their ratings and price targets for Prestige Consumer Healthcare (NYSE: PBH):

  • 5/28/2019 – Prestige Consumer Healthcare was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $31.00 price target on the stock. According to Zacks, “Shares of Prestige Consumer have lagged the industry in the past six months. The company has been witnessing declining sales for a while now and the trend continued in fourth-quarter fiscal 2019. The top line was hit by the sale of Household Cleaning unit and currency woes. Also, fiscal 2019 sales were in general hurt by a tough retail environment, stemming from consolidations and pressure of destocking. These troubles are likely to persist and hit organic sales in fiscal 2020, wherein the company expects increased A&P and G&A spending during the first half. Nonetheless, Prestige Consumer has a strong free cash flow record, which is helping it reduce debt and facilitate buybacks. Additionally, the company’s business transformation efforts and focus on buyouts are noteworthy. To this end, focus on areas like healthcare bodes well.”
  • 5/27/2019 – Prestige Consumer Healthcare had its “hold” rating reaffirmed by analysts at CIBC. They now have a $84.00 price target on the stock.
  • 5/22/2019 – Prestige Consumer Healthcare was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Shares of Prestige Consumer have lagged the industry in the past six months. The company has been witnessing declining sales for a while now and the trend continued in fourth-quarter fiscal 2019. During the quarter, the top line was hit by the sale of Household Cleaning unit and currency woes. Also, fiscal 2019 sales were in general hurt by a tough retail environment, stemming from consolidations and pressure of destocking. These troubles are likely to persist and hit organic sales in fiscal 2020, wherein the company expects increased A&P and G&A spending during the first half. Nonetheless, Prestige Consumer has a strong free cash flow record, which is helping it reduce debt and facilitate buybacks. Additionally, the company’s business transformation efforts and focus on buyouts are noteworthy.”
  • 5/10/2019 – Prestige Consumer Healthcare was downgraded by analysts at TheStreet from a “c” rating to a “d+” rating.
  • 4/30/2019 – Prestige Consumer Healthcare was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Shares of Prestige Consumer have increased and outperformed the industry in the past three months.  The company is gaining from a strong bottom-line surprise history. In fact, the third-quarter results mark the company’s fourth consecutive earnings beat. A strong financial profile boosted the bottom line in the said period. Further, the company boasts a…

(Excerpt) To read the full article , click here
Image credit: source